nimotuzumab Report issue

Biologics mAb Experimental
AACT ChEMBL MeSH

Active Ingredient History

NOW
  • Now
Nimotuzumab is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was undergoing several clinical trials.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Alternative names

hr3 | immunoglobulin g1, anti-(humanized mouse monoclonal hr3 beta1 chain anti-human epidermal growth factor receptor), disulfide with humanized mouse monoclonal hr3 kappa-chain, dimer | nimotuzumab | theracim-hr3 | theraloc | theraloc theracim

Organizations (85)

Research & Development (85)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (44)

Approved Indications (1)


 

Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (44)


 

Adenocarcinoma (Phase 2/Phase 3)

Antibody-Dependent Cell Cytotoxicity (Phase 1)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Chemoradiotherapy (Phase 3)

Colorectal Neoplasms (Phase 2)

Diffuse Intrinsic Pontine Glioma (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Drugs, Investigational (Phase 2)

Electroconvulsive Therapy (Phase 2)

ErbB Receptors (Phase 2)

Esophageal Diseases (Phase 2)

Esophageal Neoplasms (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 2/Phase 3)

General Surgery (Phase 3)

Glioblastoma (Phase 3)

Glioma (Phase 2)

Head and Neck Neoplasms (Phase 3)

Hypopharyngeal Neoplasms (Phase 2)

Immunotherapy (Phase 3)

Lung Neoplasms (Phase 2)

Mutation (Phase 1/Phase 2)

Nasopharyngeal Carcinoma (Phase 4)

Nasopharyngeal Diseases (Phase 3)

Nasopharyngeal Neoplasms (Phase 3)

Natural Killer T-Cells (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 2)

Oropharyngeal Neoplasms (Phase 2)

Palliative Care (Phase 3)

Pancreatic Neoplasms (Phase 4)

Penile Neoplasms (Phase 2)

Progression-Free Survival (Phase 2)

Prosthesis Failure (Phase 3)

Radiotherapy (Phase 2)

Rectal Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Stomach Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Uterine Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 102
  • # of Trial Organizations: 85

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue